|Articles|November 18, 2022
- Pharm Exec E-Books-11-18-2022
- Volume Sponsored eBook
- Issue 6
Investing in Next-Generation Tokenization and Real-World Data to Unlock a More Precise and Complete Patient Journey
Author(s)LexisNexis® Risk Solutions
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
The Evolving Relationship Between FDA and Biotech
4
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
5